IIPRD assists Venus Remedies in Successful Technology Out-licensing of Potentox to Adcock, South Africa

Venus Remedies Ltd. has successfully out-licensed its new generation antibiotic drug Potentox to Adcock Ingram Ltd. in South Africa earlier this year. Potentox is a Fixed-Dose Combination (FDC) of Cefepime Hydrochloride & Amikacin Sulphate developed by Venus Remedies Ltd., indicated for the treatment of Nosocomial Pneumonia & Febrile Neutropenia and available as dry powder for reconstitution before Intravenous administration. Potentox is a patented drug product in South Africa and a number of countries including the United States, Europe, Australia, New Zealand, Canada, Mexico, and Korea. Potentox replaces twin therapies of Cefepime and Amikacin with a single dose, administered as a single unit.

IIPRD had initiated the Patent/Technology out-licensing process of Potentox and focused on the South African market following our market analysis report. A few of the reasons included a large overall systemic anti-bacterial market size of around USD 280 which grows approx. 10.5% annually, and having one of the highest reported rates of pneumococcal penicillin resistance in the world, as high as 76%. South Africa has a significantly more incidence rate for diseases such as Nosocomial Pneumonia that is contracted in Hospitals. Potentox, being a first of its kind product with a synergistic effect of Cefepime & Amikacin in a single FDC, showed promise in reducing dependency on hospitals/external personnel for injecting the individual drugs.

IIPRD, as part of the exercise, focused on major players in the Antibiotics domain with a specific interest in fixed-dose combinations and, through Venus Remedies, shared non-confidential data relating to the product for further evaluation. Based on concrete interest levels, IIPRD then prepared the term sheet of the technology by taking inputs on valuation and proposed the same to Adcock for engagement on an exclusive marketing rights-based relationship.

In general, IIPRD typically follows an effective two-step approach for Patent and IP Commercialization, wherein the first step involves comprehensive Due-Diligence and Commercial Evaluation (CE) of the Patent/Technology/Product intended to be Out-Licensed from a technology, commercial, marketability, and other parameters. This step helps IIPRD understand the market potential of the technology, competing products, pricing strategies, potential licensees, the strength of Patent protection, coverage, and enforceability of the concerned patent among other commercial and technical issues. Once the commercial evaluation comes out positive, IIPRD takes the technology forward through an expansive product/technology presentation to all potential licensees and how the same would add value proposition to their product portfolio. IIPRD executes this complete step on a success basis and carries out all steps of commercialization including approach, proposition, evaluation, negotiation, and finalization through measured and defined strategies.

For Potentox, IIPRD followed on with the second step of identifying and approaching potential licensees. Amongst a list of companies identified and approached, we zeroed onto Adcock which also took a particular interest in the product and the talks were furthered and finally concluded with Venus signing an exclusive marketing alliance with Adcock. Adcock is a second-largest drugmaker in South Africa and the largest supplier of hospital and critical-care products.

About IIPRD: IIPRD is a premier IP Consulting and Technology Licensing Firm with a diversified business practice providing services in the domain of IP/Patent Support Services, Legal Support, Research and Analytics, Valuation, and Commercialization/Licensing, of Intellectual Property and allied Product Level Assets along with providing complete IP and Patent Analytics and Litigation Support Services to International Corporates and Global IP Law Firms.

About Venus Remedies Ltd: Venus Remedies Ltd. has been established in 1989. Venus is a Research & Innovation-driven Pharmaceutical Manufacturing Company with an annual turnover of about $60 million. Venus has a particular focus on Critical Care Segment, in parenteral like Cephalosporins, Carbapenems, and Oncology drugs in lyophilized form, infusions, and small volume parenterals. Venus Remedies is among the world’s 10 leading fixed dosage injectables manufacturers. Venus has a presence in about 60 countries across the globe and covering more than 75 products, with Offices in almost all Major Geographies.

Follow us on Twitter: @KnKIPLaw

Leave a Reply

Your email address will not be published. Required fields are marked *

18 − nine =

Archives

  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • September 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010